Evaluation of MVA-5T4 As a Novel Immunotherapeutic Vaccine in Colorectal, Renal and Prostate Cancer

• Amato RJ . 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.Expert Opin Biol. Ther.7(9), 1463–1469 (2007).
   PubMed Web of Science ®Google Scholar
• Harrop R , JohnJ, CarrolMW. Recombinant viral vectors: cancer vaccines.Adv. Drug Delivery Rev.588, 931–947 (2006).
   Google Scholar
• Harrop R , CarrolMW. Viral vectors for cancer immunotherapy.Front. Biosci.11, 804–817 (2006).
   PubMed Web of Science ®Google Scholar
• Starzynska T , MarshP, SchofieldPet al. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br. J. Cancer 69, 899–902 (1994).
   PubMed Web of Science ®Google Scholar
• Griffiths RW , GilhamDR, DangoorAet al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br. J. Cancer 93(6), 670–677 (2005).
   PubMed Web of Science ®Google Scholar
• Barrow KM , WardCM, RutterJ, AliS, SternPL. Embryonic expression of murine 5T4 oncofetal antigen is associated with morphogenetic events at implantation and in developing epithelia.Dev. Dyn.233(4), 1535–1545 (2005).
   PubMed Web of Science ®Google Scholar
• Hole N , SternPL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody.Br. J. Cancer57, 237–246 (1988).
   Web of Science ®Google Scholar
• Southall P , BoxerG, BagshawKet al. Immunological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer 61, 89–95 (1990).
   PubMed Web of Science ®Google Scholar
• Southgate TD , McGinnOJ, CastroFVet al. CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS ONE 5(4), e9982 (2010).
   PubMedGoogle Scholar
• Sutter G , MossB. Non-replicating vaccinia vector efficiently expresses recombinant genes.Proc. Natl Acad. Sci. USA89, 10847–10851 (1992).
   PubMed Web of Science ®Google Scholar
• Harrop R , Ryan, MG, MyersKAet al. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol. Immunother. 55(9), 1081–1090 (2006).
   PubMed Web of Science ®Google Scholar
• Mulryan K , RyanMG, MyersKAet al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol. Cancer Ther. 1, 1129–1137 (2002).
   PubMed Web of Science ®Google Scholar
• Harrop R , ConnollyNB, RedchenkoIet al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II trial. Clin. Cancer Res. 12(11), 3416–3424 (2006).
   PubMed Web of Science ®Google Scholar
• Harrop R , DruryN, ShinglerWet al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol. Immunother. 57(7), 977–986 (2008).
   PubMed Web of Science ®Google Scholar
• Harrop R , DruryN, ShinglerWet al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res. 13(15 Pt 1), 4487–4494 (2007).
   PubMed Web of Science ®Google Scholar
• Elkord E , DangoorA, BurtDJet al. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol. Immunother. 58(10), 1657–1667 (2009).
   PubMed Web of Science ®Google Scholar
• Hawkins RE , MacDermottC, ShablakAet al. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-α. J. Immunother. 3(4), 424–429 (2009).
   Google Scholar
• Amato RJ , ShinglerW, GoonewardenaMet al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a Phase 2 trial. J. Immunother. 32(7), 765–772 (2009).
   PubMed Web of Science ®Google Scholar
• Kaufman HL , TabackB, ShermanWet al. Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J. Transl Med. 7, 2 (2009).
   PubMed Web of Science ®Google Scholar
• Amato R , ShinglerW, NaylorSet al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a Phase II trial. Clin. Cancer Res. 14(22), 7504–7510 (2008).
   PubMed Web of Science ®Google Scholar
• Amato RJ , DruryN, NaylorSet al. Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): a Phase 2 trial. J. Immunother. 31(6), 577–585 (2008).
   PubMed Web of Science ®Google Scholar
• Amato RJ , HawkinsRE, KaufmanHLet al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled Phase III study. Cancer Res. 16(22), 5539–5547 (2010).
   Web of Science ®Google Scholar
• Motzer RJ , HutsonTE, TomczakPet al. Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N. Engl. J. Med. 256(2), 115–124 (2007).
   Google Scholar
• Huang S , HoustonP. Targeting mTOR signaling for cancer therapy.Curr. Opin Pharmacol.3(4), 371–377 (2003).
   PubMed Web of Science ®Google Scholar
• Hudes G , CarducciM, TomczakPet al. Temsirolimus, interferon-α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Harrop R , ShinglerWH, McDonaldMet al. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol. Immunother. 60, 829–837 (2011).
   PubMed Web of Science ®Google Scholar

Website

• American Cancer Society. Cancer Facts and Figures 2011. www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf
   Google Scholar